Immunome (IMNM) EBT Growth (3y) (2022 - 2026)

Immunome (IMNM) EBT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.22%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 12.16%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 86.16%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 41.79%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 95.61%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 38.36%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 64.03%
10 Immunome 3.09 Bn 2.57 Bn - -149.05%

Historic Data

Download Data
DateValue
Jun 30, 2026 -149.05%
Mar 31, 2026 -276.65%
Dec 31, 2025 -108.16%
Sep 30, 2025 -104.39%
Jun 30, 2025 -87.15%
Mar 31, 2025 -56.32%
Dec 31, 2024 -120.59%
Sep 30, 2024 -146.82%
Jun 30, 2024 -49.05%
Mar 31, 2024 -221.16%
Dec 31, 2023 -185.92%
Sep 30, 2023 2.94%
Jun 30, 2023 -80.55%
Mar 31, 2023 -19.61%
Dec 31, 2022 -40.51%
Sep 30, 2022 -63.37%